Biotech Co. Submits CTA for its 2nd Trial Launching in 2015
RepliCel's autologous cell therapy, RCS-01, to be investigated as a potential treatment for aged and UV-damaged skin.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.